An increased consideration for Quality of Life combined with an aging population (often with significant co-morbidities) has driven the demand for organ-sparing options for “operable” patients with small tumors in the lower third of the rectum.
Papillon+ X-ray Brachytherapy rectal cancer treatment enables the oncologist to deliver a very high dose (30Gy) per fraction to the tumour or to the tumour bed. The total dose is dependent on whether other treatment modalities are used in conjunction with Papillon radiotherapy. The use of Papillon + X-ray Brachytherapy offers a significant advantage for some patients and may be suitable for use as the sole modality or as an adjuvant treatment.
Ariane Medical Systems Ltd
151 Mansfield Road
Alfreton DE55 7JQ United Kingdom